On Friday, Zai Lab Limited ADR (NASDAQ: ZLAB) opened lower -6.78% from the last session, before settling in for the closing price of $36.01. Price fluctuations for ZLAB have ranged from $16.01 to $44.34 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -3.18%. Company’s average yearly earnings per share was noted 47.82% at the time writing. With a float of $109.14 million, this company’s outstanding shares have now reached $110.59 million.
Let’s determine the extent of company efficiency that accounts for 1869 employees. In terms of profitability, gross margin is 63.45%, operating margin of -64.09%, and the pretax margin is -60.26%.
Zai Lab Limited ADR (ZLAB) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Zai Lab Limited ADR is 1.31%, while institutional ownership is 50.50%. The most recent insider transaction that took place on Jul 02 ’25, was worth 249,147. In this transaction Chairperson & CEO of this company sold 7,072 shares at a rate of $35.23, taking the stock ownership to the 536,962 shares. Before that another transaction happened on Jul 02 ’25, when Company’s Officer proposed sale 7,072 for $35.23, making the entire transaction worth $249,144.
Zai Lab Limited ADR (ZLAB) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 47.82% per share during the next fiscal year.
Zai Lab Limited ADR (NASDAQ: ZLAB) Trading Performance Indicators
Check out the current performance indicators for Zai Lab Limited ADR (ZLAB). In the past quarter, the stock posted a quick ratio of 3.09. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.87.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.50, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach 0.64 in one year’s time.
Technical Analysis of Zai Lab Limited ADR (ZLAB)
Looking closely at Zai Lab Limited ADR (NASDAQ: ZLAB), its last 5-days average volume was 0.82 million, which is a drop from its year-to-date volume of 1.02 million. As of the previous 9 days, the stock’s Stochastic %D was 61.83%.
During the past 100 days, Zai Lab Limited ADR’s (ZLAB) raw stochastic average was set at 46.42%, which indicates a significant increase from 27.12% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.11 in the past 14 days, which was lower than the 1.53 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $34.28, while its 200-day Moving Average is $30.70. However, in the short run, Zai Lab Limited ADR’s stock first resistance to watch stands at $34.65. Second resistance stands at $35.73. The third major resistance level sits at $36.28. If the price goes on to break the first support level at $33.02, it is likely to go to the next support level at $32.47. Should the price break the second support level, the third support level stands at $31.39.
Zai Lab Limited ADR (NASDAQ: ZLAB) Key Stats
There are currently 111,078K shares outstanding in the company with a market cap of 3.71 billion. Presently, the company’s annual sales total 398,990 K according to its annual income of -257,100 K. Last quarter, the company’s sales amounted to 106,490 K and its income totaled -48,440 K.
